Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (SLNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,948,026
  • Shares Outstanding, K 43,117
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,990 K
  • EBIT $ -142 M
  • EBITDA $ -141 M
  • 60-Month Beta -1.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.63

Options Overview Details

View History
  • Implied Volatility 60.30% ( -6.27%)
  • Historical Volatility 45.41%
  • IV Percentile 25%
  • IV Rank 18.29%
  • IV High 145.78% on 03/05/24
  • IV Low 41.16% on 11/26/24
  • Put/Call Vol Ratio 11.08
  • Today's Volume 882
  • Volume Avg (30-Day) 2,224
  • Put/Call OI Ratio 1.95
  • Today's Open Interest 69,237
  • Open Int (30-Day) 83,473

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.68
  • Number of Estimates 4
  • High Estimate -0.58
  • Low Estimate -0.79
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -106.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.32 +3.79%
on 12/19/24
60.92 -26.20%
on 11/25/24
-12.82 (-22.19%)
since 11/22/24
3-Month
43.32 +3.79%
on 12/19/24
60.92 -26.20%
on 11/25/24
-3.18 (-6.61%)
since 09/23/24
52-Week
35.70 +25.94%
on 01/04/24
60.92 -26.20%
on 11/25/24
+7.07 (+18.66%)
since 12/22/23

Most Recent Stories

More News
Soleno Therapeutics Secures Up to $200 Million in Loan Agreement with Oxford Finance

Soleno Therapeutics secures up to $200 million in financing to support its drug development and anticipated commercial activities.Quiver AI SummarySoleno Therapeutics, Inc. has secured a loan and security...

SLNO : 44.37 (-1.79%)
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

SLNO : 44.37 (-1.79%)
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

SLNO : 44.37 (-1.79%)
Soleno Therapeutics Announces FDA Extension of NDA Review for DCCR Tablets in Prader-Willi Syndrome

FDA extends review of Soleno’s NDA for DCCR tablets treating Prader-Willi syndrome; new decision date is March 27, 2025.Quiver AI SummarySoleno Therapeutics, Inc. announced that the FDA has extended...

SLNO : 44.37 (-1.79%)
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

SLNO : 44.37 (-1.79%)
Soleno Therapeutics to Present DCCR Clinical Data for Prader-Willi Syndrome at 62nd Annual ESPE Meeting

Soleno Therapeutics will present DCCR clinical data for Prader-Willi syndrome at the upcoming ESPE Meeting in Liverpool.Quiver AI SummarySoleno Therapeutics, Inc. announced that it will present data from...

SLNO : 44.37 (-1.79%)
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

SLNO : 44.37 (-1.79%)
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

SLNO : 44.37 (-1.79%)
Soleno Therapeutics to Participate in Upcoming November Investor Conferences

SLNO : 44.37 (-1.79%)
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.

SLNO : 44.37 (-1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief....

See More

Key Turning Points

3rd Resistance Point 48.82
2nd Resistance Point 47.69
1st Resistance Point 46.44
Last Price 44.37
1st Support Level 44.06
2nd Support Level 42.93
3rd Support Level 41.68

See More

52-Week High 60.92
Fibonacci 61.8% 51.29
Fibonacci 50% 48.31
Fibonacci 38.2% 45.33
Last Price 44.37
52-Week Low 35.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar